← SynDRA
PAZOPANIB
SynDRA canonical compound SYN0016262 — structure-anchored drug synonym record
| Clinical phase | Launched |
|---|
| Approval status | Approved · Rx |
|---|
| Primary target(s) | PDGFRB |
|---|
| Mechanism of action | VEGFR inhibitor |
|---|
| Indication | renal cell carcinoma (RCC) | soft tissue sarcoma (STS) |
|---|
| Disease area | oncology |
|---|
All known targets
- KDR
- KIT
- PDGFRB
- FLT1
- FLT4
- FGFR1
- CSF1R
- PDGFRA
- FGFR3
- ITK
- BRAF
- LCK
Mechanisms of action (all sources)
- KIT INHIBITOR
- PDGFR inhibitor
- VEGFR inhibitor
- CSF1R INHIBITOR
- Macrophage colony stimulating factor receptor inhibitor
- Stem cell growth factor receptor inhibitor
- LCK INHIBITOR
- Tyrosine-protein kinase LCK inhibitor
- FGFR3 INHIBITOR
- Fibroblast growth factor receptor 3 inhibitor
- FGFR1 INHIBITOR
- Fibroblast growth factor receptor 1 inhibitor
Drug classes
- Protein Kinase Inhibitors
- Kinase Inhibitor
- Cytochrome P450 2D6 Inhibitors
- Cytochrome P450 3A4 Inhibitors
- Cytochrome P450 2C8 Inhibitors
ATC classes
- L01E · PROTEIN KINASE INHIBITORS
Cross-references
Synonyms
- GW786034B
- votrient
- GW 786034
- pazopanib hydrochloride
- pazopanib HCl
- GW-786034
- GW786034
- NSC-752782
- Votrient
- Pazopanib HCl
- Votrient (TN)
- 5-((4-((2,3-dimethyl-2H-indazol-6-yl)(methyl)amino)pyrimidin-2-yl)amino)-2-methylbenzenesulfonamide
- 5-({4-[(2,3-dimethyl-2H-indazol-6-yl)(methyl)amino]pyrimidin-2-yl}amino)-2-methylbenzene-1-sulfonamide
- NSC 752782
- 7RN5DR86CK
- GW 78603
- CHEBI:71219
- NCGC00188865-01
- 5-[[4-[(2,3-dimethylindazol-6-yl)-methylamino]pyrimidin-2-yl]amino]-2-methylbenzenesulfonamide
- 5-[[4-[(2,3-dimethyl-2h-indazol-6-yl)methylamino]-2-pyrimidinyl]amino]-2-methylbenzenesulfonamide
- 5-[4-[(2,3-Dimethyl-2H-indazol-6-yl)-methyl-amino]-pyrimidin-2-ylamino]-2-methyl-benzenesulfonamide
- Pazopanib [INN]
- 5-({4-[(2,3-Dimethyl-2H-indazol-6-yl)(methyl)amino]pyrimidin-2-yl}amino)-2-methylbenzenesulfonamide
- Benzenesulfonamide, 5-((4-((2,3-dimethyl-2H-indazol-6-yl)methylamino)-2-pyrimidinyl)amino)-2-methyl-
- Pazopanib (GW-786034)
- CAS-444731-52-6
- Pazopanib [INN:BAN]
- UNII-7RN5DR86CK
- pazopanibum
- HSDB 8210
- Pazopanib- Bio-X
- Benzenesulfonamide, 5-[[4-[(2,3-dimethyl-2H-indazol-6-yl)methylamino]-2-pyrimidinyl]amino]-2-methyl-
- MFCD11616589
- GW 786034B
- indazolylpyrimidine 13
- Pazopanib (free base)
- Kinome_3790
- GW780604
Reported adverse events
- Alopecia
- Asthenia
- Bradycardia
- Cough
- Dizziness
- Dysgeusia
- Fatigue
- Fistula
- Gastrointestinal pain
- Headache
- Hypertension
- Hypothyroidism
Look up PAZOPANIB in the interactive SynDRA portal →